'Mitotherapy' for Heart Failure. [comentario]
Por: Sanchis Gomar, Fabián [Instituto de Investigación imas12]
| Lucía, Alejandro [Instituto de Investigación i+12].
Colaborador(es): Instituto de Investigación imas12.
Tipo de material: 
ArtículoEditor: Trends in molecular medicine, 2016Descripción: 22(4):267-9.Recursos en línea: Solicitar documento Resumen: Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Comentario
|
PC18008 (Navegar estantería) | Disponible |
Navegando Hospital Universitario 12 de Octubre Estantes Cerrar el navegador de estanterías
Formato Vancouver:
Sanchís Gomar F, Lippi G, Lucía A. 'Mitotherapy' for Heart Failure. Trends Mol Med. 2016 Apr;22(4):267-9.
PMID: 26965961
Contiene 12 referencias
Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.
No hay comentarios para este ejemplar.